Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need
"Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.
- "Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.
- "These numbers and our growing understanding of these diseases are leading to a sharp rise in global demand for direct oral anticoagulants.
- We want to help labs meet this increased need for testing to better inform patient care.
- These tests can be used for both assessing the anti-Xa activity of heparin therapy as well as the three authorised Factor Xa inhibitors.